ArcticDx Inc. is a molecular diagnostic company with expertise in the design, development and commercialization of validated molecular diagnostic tests. Our business model is focused towards the rapid commercialization of Intellectual Property (IP) from international gene discovery programs. ArcticDx: 1.Acquires validated molecular IP; 2.Validates and commercializes customized diganostic tests; 3.Out-licenses validated diagnostic tests internationally. Macula Risk® PGx is a combined prognostic and pharmacogenetic DNA test designed to determine a patient’s risk of progression to advanced Age-related Macular Degeneration (AMD) and aid in the selection of appropriate eye vitamins for AMD based on his or her individual genetic risk profile. Macula Risk PGx and Vita Risk™ are covered by most insurers for patients with a diagnosis of AMD.